Ig Vena (Human Normal Immunoglobulin (Iv))

It supplies a broad spectrum of pooled IgG antibodies derived from thousands of donors, delivering passive immunity and modulating immune responses through Fc‑receptor binding, complement inhibition, and neutralization of pathogens.

The dose is individualized; a prescribing clinician determines the amount based on patient weight, IgG trough levels, and clinical response, typically expressed in grams per kilogram administered over several hours.

Safety data are limited; the product is classified as pregnancy category unknown. Use is considered only if the potential benefit justifies potential risk, and decisions should be made by the treating physician.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping options and necessary import documentation.

Ig Vena contains pooled human IgG similar to other IVIG preparations, offering comparable efficacy in immunoglobulin replacement. Differences may lie in manufacturing processes, stabilizers, and concentration, which can affect infusion rates, tolerability and storage requirements; clinicians choose based on patient needs and product availability.

Store at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Once removed from refrigeration, use within the time frame specified in the product label and keep the solution at room temperature no longer than recommended before administration.

Ig Vena is given as an intravenous infusion. The solution is diluted in an appropriate compatible fluid and infused slowly, typically over 2‑4 hours for the first infusion, with the rate increased in subsequent administrations as tolerated. Administration should be performed by qualified healthcare professionals.

Serious adverse events include anaphylactic or severe allergic reactions, thromboembolic complications, acute renal failure, hemolysis and aseptic meningitis. Patients should be monitored closely during and after infusion, and any signs of these conditions require immediate medical attention.

Ig Vena is contraindicated in patients with known severe IgA deficiency who have anti‑IgA antibodies, as they are at high risk for anaphylaxis. It should also be avoided in individuals with a history of severe hypersensitivity to immunoglobulin products or any of the excipients.